Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Express Scripts
Johnson and Johnson
Argus Health
Merck
Mallinckrodt
Citi
Deloitte

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064047

« Back to Dashboard

NDA 064047 describes NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, which is a drug marketed by Amring Pharms, Bausch And Lomb, Ipharm, and Watson Labs, and is included in four NDAs. It is available from two suppliers. Additional details are available on the NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN profile page.

The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN is gramicidin; neomycin sulfate; polymyxin b sulfate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the gramicidin; neomycin sulfate; polymyxin b sulfate profile page.
Summary for 064047
Pharmacology for NDA: 064047
Suppliers and Packaging for NDA: 064047
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN gramicidin; neomycin sulfate; polymyxin b sulfate SOLUTION/DROPS;OPHTHALMIC 064047 ANDA Bausch & Lomb Incorporated 24208-790 N 24208-790-62
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN gramicidin; neomycin sulfate; polymyxin b sulfate SOLUTION/DROPS;OPHTHALMIC 064047 ANDA A-S Medication Solutions 50090-0247 N 50090-0247-0

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML
Approval Date:Jan 31, 1996TE:ATRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Boehringer Ingelheim
Dow
Harvard Business School
McKesson
Cipla
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.